June 13, 20061 Biotechnology/Chemical/Pharmaceutical Customer Partnership USPTO Study on Restriction Reform and TC1600 Restriction Practice Action Plan.

Slides:



Advertisements
Similar presentations
1 TC1600 Restriction Practice Action Plan and Unity of Invention Study Bruce Kisliuk Group Director, TC1600 United States Patent and Trademark Office.
Advertisements

Brian A. Harris-Kojetin, Ph.D. Statistical and Science Policy
1 TC1600-Quality Assurance Bennett Celsa QAS Joseph Woitach SPE June 4, 2013.
Bicoastal Biotechnology/Chemical/Pharmaceutical Customer Partnership Meeting RCE Progress Update Daniel Sullivan Director, TC1600 September 17, 2014.
Intellectual Property Rights Regulations in Russia: Case of Government-Supported R&D Irina Dezhina Leading Researcher, Ph.D. Institute for the Economy.
1 1 1 AIPLA American Intellectual Property Law Association USPTO Updates Including Glossary Pilot Program Chris Fildes Fildes & Outland, P.C. IP Practice.
VIEWS ON THE NEW INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY PROCEDURE (“MERGER OF PCT CHAPTERS I AND II”): ADVANTAGES, PROBLEMS AND FUTURE OPPORTUNITIES.
September 14, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December.
Comments of American Intellectual Property Law Association Public meeting January 13, 2009 Patent Cooperation Treaty Presenter: Carl Oppedahl Oppedahl.
Community Patent Robert Clarke – Deputy Director Office of Patent Legal Administration
Q. TODD DICKINSON EXECUTIVE DIRECTOR, AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA) USPTO PUBLIC MEETING JULY 20, 2010 AIPLA Comments: Enhanced.
July 8, Enhanced Examination Timing Control Robert A. Clarke Deputy Director Office of Patent Legal Administration
PPAC Outreach Effort Andrew Faile Assistant Deputy Commissioner for Patents.
February 2012 Presentation to the Biotechnology/Chemical/Pharmaceutical Customer Partnership Introduction to the Cooperative Patent Classification (CPC)
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
© 3M All Rights Reserved. July 20, 2010 Response to USPTO Request for Public Comment on Enhanced Examination Timing Control Initiative.
Safekeeping of 35 U.S.C. 156 Extensions
by Eugene Li Summary of Part 3 – Chapters 8, 9, and 10
Patent Quality Assurance Program. 2 Office of Patent Quality Assurance (OPQA) Deputy Commissioner for Patent Operations Office of Patent Quality Assurance.
Applications for Intellectual Property International IP Protection IP Enforcement Protecting Software JEFFREY L. SNOW, PARTNER NATIONAL SBIR/STTR CONFERENCE.
Project Prioritization Process ASPCC Update December 14, 2005.
Part II Objectives F Describe how policies and procedures are used F Identify different types of P & P F Describe the purpose and components of a Policy.
Canada OPICCIPO Office de la propriété intellectuelle du Canada Un organisme d’industrie Canada Canadian Intellectual Property Office An Agency of Industry.
Current and Future USPTO Practice RESTRICTION PRACTICES AT THE USPTO 1 © AIPLA 2015.
1 United States Patent and Trademark Office Revised PCT International Search and Preliminary Examination Guidelines Biotech/ChemPharm Customer Partnership.
December 8, Changes to Patent Fees Under the Consolidated Appropriations Act, 2005 (H.R. 4818)(upon enactment) and 35 U.S.C. 103(c) as Amended by.
February 19, Recent Changes and Developments in USPTO Practice Prepared by: Office of Patent Legal Administration (OPLA) Robert J. Spar, DirectorJoni.
Eric R. Johnson Hillsborough County, (Tampa) FL
J.A.Kemp & Co. London Munich Oxford. FICPI ABC MEETING 2007 EPC 2000 Alan M. Senior 30 May 2007.
Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Biological Deposits.
Notice of Proposed Rule Making Affecting Claims That Recite Alternatives 1 Robert Clarke, Director Office of Patent Legal Administration (571)
1 AIPLA Biotech Committee Meeting Washington D.C., October 14, 2004 Jasemine C. Chambers, Ph.D., J.D. Director Technology Center 1600 USPTO (571)
John Stem 7 th Annual Summit on VR PEQA Louisville, Kentucky.
1 Biotechnology/Chemical/Pharmaceutical Customer Partnership June 1, 2010 Valencia Martin-Wallace – Director, Technology Center 2400.
Module #3 Budgeting. What is Budgeting? Budgeting is the process of allocating resources to the prioritized needs of a school district. Budgeting is the.
Second expert group meeting on Draft fiche on delegated act on the European code of conduct on partnership (ECCP) Cohesion Policy
USPTO Patent Quality Composite presented to Biotechnology/Chemical/Pharmaceutical Customer Partnership September 5, 2012 by Martin Rater Statistician USPTO,
Biotech Customer Partnership August 3, 2004 Jasemine C. Chambers, Ph.D., J.D. Director Technology Center 1600 USPTO (571)
Corporate Practice Committee August 18, 2015 Randi L. Karpinia, Director Intellectual Property Law, Motorola Solutions Inc. Adapting to a Changing Business.
GOVERNOR’S EARLY CHILDHOOD ADVISORY COUNCIL (ECAC) September 9, 2014.
Claims and Continuations Final Rule Overview Briefing for Examiners 1.
U.S. Department of Transportation Pipeline and Hazardous Materials Safety Administration Part 190 NPRM: Administrative Procedures - 1 -
Lawrence T. Welch April, 2003 Company Confidential Copyright © 2003 Eli Lilly and Company FICPI/AIPLA Colloquium Reform of the Patent Cooperation Treaty.
FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice Julie Burke TC1600 Quality Assurance Specialist
Consideration Towards Development of Intellectual Property System Dr. Li Yuguang Deputy Commissioner the State Intellectual Property Office of P. R. China.
OCFO - Financial Status of USPTO May 7, FY 2010 Status Authorized level of $1,887.0 million Mid-year Budget Execution Review currently underway.
1 Restriction Petition Survey; A Few Helpful Hints Julie Burke TC1600 Special Program Examiner
1 1 1 AIPLA Firm Logo American Intellectual Property Law Association U.S. Implementation of the Hague Agreement For Designs John (Jack) J. Penny, V Event.
Chris Fildes FILDES & OUTLAND, P.C. IP Practice in Japan Committee Pre-Meeting AIPLA Annual Meeting, October 20, 2015 USPTO PILOT PROGRAMS 1 © AIPLA 2015.
James Toupin – General Counsel February 1, Summary of Proposed Rule Changes to Continuations, Double Patenting, and Claims.
PCT Reform - FICPI views Jan Modin Chair, FICPI CET Group 3 PCT Reform - FICPI views Jan Modin Chair, FICPI CET Group 3 Colloquium on PCT –Nice, 9 April.
JPO’s Initiatives for World‘s Best Examination Quality January, 2015 JAPAN PATENT OFFICE.
1 Biotech/Chem/Pharm Customer Partnership Meeting June 15, 2005 USPTO Study on Restriction Reform and Update on TC1600 Restriction Practice Action Plan.
Bruce Kisliuk Group Director, Technology Center 1600.
FY 2010 and FY 2011 USPTO Financial Report Trademark Public Advisory Committee Meeting February 25, 2010.
1 Drivers for Implementation of TC 1600 Restriction Practice Action Plan: Public comments from bar groups, and customer partnerships starting before the.
PP 620: Public Policy and Health Administration Unit One Seminar Kris R. Foote, J.D., M.P.A., M.S.W. Kaplan University.
Accelerated Patent Examination: Green Technology A Summary of Global Initiatives, with specific discussion of the US Speaker: Matt Prater Preparation help.
DG Enterprise and Industry European Commission Standardisation Aspects of ICT and e-Business Antonio Conte Unit D4 - ICT for Competitiveness and Innovation.
Alexandria, Virginia July 21, 2014
Evaluating a Task-based English Course: A Proposed Model
FDA’s IDE Decisions and Communications
PATENT LAW TREATY Gena Jones Senior Legal Advisor
The IAASB’s Future Strategy
Unity of invention – outcome of the IP5 work MEETING OF INTERNATIONAL AUTHORITIES – QUALITY SUBGROUP Camille Bogliolo (PCT Affairs) and Luigi Petrucci.
The National Association of Patent Practitioners (NAPP)
I. Review of TC1600 Restriction Practice Action Plan
Boston Patent Law Association Annual Meeting
Presentation transcript:

June 13, Biotechnology/Chemical/Pharmaceutical Customer Partnership USPTO Study on Restriction Reform and TC1600 Restriction Practice Action Plan Kathleen Kahler Fonda, Ph.D., J.D. Legal Advisor, Office of Patent Legal Administration U.S. Patent &Trademark Office (571) ;

June 13, USPTO Study on Restriction Reform  Background  Four Options  Steps of the Study  Green Paper Recommendations Biotechnology/Chemical/Pharmaceutical Customer Partnership

June 13, USPTO Study on Restriction Reform Background  Study possible reforms to restriction standards applicable to all technologies  Part of 21 st Century Strategic Plan

June 13, USPTO Study on Restriction Reform Background (continued)  Strategic Plan  Initiate a study of the changes needed to implement a Patent Cooperation Treaty (PCT) style Unity of Invention standard in the United States.  Public Comment Notice published May 2003  No consensus to go to a PCT-style Unity standard.  Suggestions for other options made.  Revision of Study posted November 2003  Summary of public comments.  Study expanded to include four restriction reform options.

June 13, USPTO Study on Restriction Reform  Four Options  Option I: Current 35 U.S.C. §121 “independent or distinct” standard and option to request and pay for examination of up to 2 additional independent or distinct inventions for an additional fee.  Option II: Current PCT “unity of invention” standard (modified to require that any purported special technical/common feature comply with 35 U.S.C. §112, 1 st paragraph), and option to request and pay for examination of up to 2 additional inventions that lack unity of invention for an additional fee.

June 13, USPTO Study on Restriction Reform  Four Options (Continued)  Option III: New three-tiered structure based on the related-ness of the inventions (substantially similar, related, and unrelated), and fees would be associated with the related-ness.  Option IV: Re-interpreted “independent and distinct” standard.

June 13, USPTO Study on Restriction Reform  Steps of the Study  Develop details of the standards for each the four options.  Sample a representative number of restrictions (about 500), review and apply standard under each of the four options.  Compile the data from the reviews and validate data.  Perform the business analysis and impacts based on review data and process changes.  Draft the “Green Paper.”

June 13, USPTO Study on Restriction Reform  Steps of the Study (Continued)  June 6, 2005 – Published Green Paper  “Notice of Availability of and Request for Comments on Green Paper Concerning Restriction Practice,” 70 FR 107 (June 6, 2005)  Green Paper available at  Comment period ended September 15,  Next Steps – Assess the public comments prior to considering the desirability of drafting any proposed legislative changes in a final “White Paper.”

June 13, USPTO Study on Restriction Reform Green Paper Conclusions/Recommendations:  Options 3 and 4 –  Development of standards highlights the difficulty in formulation of any new standard.  Not considered viable for implementation.  Options 1 and 2 – Somewhat more promising in terms of the standards being more workable to implement. The business analysis indicates these would not achieve a desired balance due to workload and pendency impacts.  The process of improving the quality and predictability of restriction requirements must be a collaborative effort.  This paper and the TC1600 Restriction Action Plan represent only the first step in an ongoing endeavor to discover feasible solutions.

June 13, USPTO Study on Restriction Reform Green Paper Conclusions/Recommendation (Continued):  The Office requests comments from the public on:  The desirability of conducting further study on Options 1 and 2.  Whether the perceived desirability justifies the costs to the Office of continuing the study  The impact on the system as a whole.  Appropriate legislation would need to be enacted in the event a decision to implement Option 1 or 2 is made.  Implementation of Option 1 would not be viable without a revision to the fees for search/examination, issue and maintenance.  Implementation of Option 2 would require revision to 35 U.S.C. § 121 in addition to the same fee revisions required to implement Option 1.

June 13, USPTO Study on Restriction Reform  Comments Received on Green Paper Concerning Restriction Practice  16 Responders:  Groups:  National Association of Patent Practitioners (NAPP)  The Bar Association of the District of Columbia (BADC)  Biotechnology Industry Organization (BIO)  International Federation of Intellectual Property Attorneys (FICPI)  Japan Intellectual Property Association (JIPA)  National Institutes of Health (NIH)  Corporations:  Genentech, Inc.  IBM Corporation

June 13, USPTO Study on Restriction Reform  Comments Received on Green Paper Concerning Restriction Practice  16 Responders (cont’d)  Individuals  Jon Henry  Robert Johnson  Todd Juneau  Gordon Lindeen  Raymond S. Parker, III and Julie Anne Knight  James Lindon  Paul Morgan  Robert J. Webster

June 13, USPTO Study on Restriction Reform  Comments Received on Green Paper Concerning Restriction Practice  Breakdown of Support for Options  Option 1.Current national restriction practice with an option to pay for the examination of additional invention(s) within the original application.  Five : BADC, IBM (partial support), Johnson (partial support), Juneau, Morgan

June 13, USPTO Study on Restriction Reform  Comments Received on Green Paper Concerning Restriction Practice  Breakdown of Support for Options  Option 2. Modified PCT unity of invention standard with: 1) an additional requirement that the special technical/common feature comply with 35 U.S.C. § 112, 1st paragraph and 2) an option to pay for additional invention(s).  Eight : NAPP (second choice), BIO (partial support), FICPI, JIPA, Genentech (partial support), IBM (partial support), Parker et al. (partial support), Webster (partial support)

June 13, USPTO Study on Restriction Reform  Comments Received on Green Paper Concerning Restriction Practice  Breakdown of Support for Options (cont’d)  Option 3. Three-tiered fee structure dependent upon the search burden associated with, and the presence of different patentability issues between, various inventions.  Two : BIO (partial support), Genentech (partial support)  Option 4. Independent and distinct standard (as opposed to independent or distinct).  Four : NAPP (first choice), Henry (partial support), Lindon, Parker et al.

June 13, USPTO Study on Restriction Reform  Comments Received on Green Paper Concerning Restriction Practice  Recurring Themes  support for reform; dissatisfaction with current practice  only one comment against reform; many in favor  need for predictability/uniformity of restriction process  "independent and distinct" vs. "independent or distinct"  many responders believe the Office is ignoring the statute

June 13, USPTO Study on Restriction Reform  Comments Received on Green Paper Concerning Restriction Practice  Recurring Themes (cont’d)  financial considerations  balanced view; the Office needs resources but filing can be expensive  large number of divisionals not desirable  international harmonization  timing of examination for 112 issues  Comments addressing this issue see no need to consider 112 at the time of restriction

June 13, TC1600 Restriction Practice Action Plan  Background  Five Initiatives  Phase I Examiner Training  Next Steps

June 13, TC1600 Restriction Practice Action Plan Background:  Announced October 2003  Improve quality and consistency of restrictions in TC1600

June 13, TC1600 Restriction Practice Action Plan The action plan includes 5 initiatives: 1.Emphasis On Rejoinder Practice Policy memos to examiners 2.Examiner Training On Restriction Practice Phase I training completed and training materials posted Aug Publish Examples Of Claim Sets Part of training materials, more to come in subsequent Phases 4.Enhanced Review Of Restriction Requirements Rolling review of Art Units 5.Continuous Assessment Reviews of restrictions and restriction-related petition decisions

June 13, TC1600 Restriction Practice Action Plan  Phase I Examiner Training (August 2004)  Focused on restriction fundamentals  Basic criteria for restrictions  Linking claims  Rejoinder opportunities  Included example claims and restriction requirements  Next Steps  Examiner training on the revised MPEP Chapter 800 (Restriction)  Examiner training on genus/species

June 13, Biotechnology/Chemical/Pharmaceutical Customer Partnership Thank You Kathleen Kahler Fonda, Ph.D., J.D. Legal Advisor, Office of Patent Legal Administration U.S. Patent &Trademark Office (571) ;